1. Home
  2. LTBR vs DBVT Comparison

LTBR vs DBVT Comparison

Compare LTBR & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lightbridge Corporation

LTBR

Lightbridge Corporation

HOLD

Current Price

$14.71

Market Cap

578.2M

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$18.21

Market Cap

508.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTBR
DBVT
Founded
1992
2002
Country
United States
France
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
578.2M
508.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LTBR
DBVT
Price
$14.71
$18.21
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$24.46
AVG Volume (30 Days)
1.1M
452.4K
Earning Date
11-05-2025
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,502,000.00
Revenue This Year
N/A
$1,768.71
Revenue Next Year
N/A
$1,028.88
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.37
$2.74
52 Week High
$31.34
$21.50

Technical Indicators

Market Signals
Indicator
LTBR
DBVT
Relative Strength Index (RSI) 38.36 69.25
Support Level $15.68 $17.86
Resistance Level $17.19 $21.50
Average True Range (ATR) 1.14 1.22
MACD 0.15 0.62
Stochastic Oscillator 13.25 65.97

Price Performance

Historical Comparison
LTBR
DBVT

About LTBR Lightbridge Corporation

Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: